IntoCell focuses on advanced cellular technologies aimed at enhancing therapeutic applications. The company specializes in the development of innovative cell-based solutions that leverage the power of stem cells and engineered cell lines. Their approach includes the use of proprietary platforms for cell reprogramming and differentiation, which enable the generation of specific cell types for targeted treatments. This technology is designed to improve the efficacy and safety of therapies, particularly in regenerative medicine and disease modeling.

Additionally, IntoCell emphasizes the importance of precision in their methodologies, utilizing cutting-edge techniques such as CRISPR gene editing and high-throughput screening. These technologies facilitate the customization of cellular products, allowing for tailored therapeutic options that can address a variety of medical conditions. By integrating these advanced technologies, IntoCell aims to accelerate the development of next-generation therapies that can significantly impact patient outcomes and advance the field of cell therapy.

South Korea

IntoCell is a Korea-based biotechnology company dedicated to the development and commercialisation of novel antibody drug conjugate (ADC) platform technologies.

IntoCell

Company Details